TD2 Oncology buyer-window signal capture

Evidence

• Nuvectis's September 24, 2026 wire release, announcing China breakthrough therapy designation for NXP200 in high-grade glioma, quotes the CEO that the company continues to advance NXP200 toward a US IND submission in the fourth quarter; the licensed territory is ex-Greater China.
• Nuvectis's second-quarter results release, filed as an 8-K exhibit on August 4, 2026, states under NXP200 that U.S. regulatory efforts are underway and an IND submission is expected in the fourth quarter of 2026.
• Nuvectis Pharma, Fort Lee, New Jersey, reported 16 full-time employees in its 10-Q for the quarter ended June 30, 2026, filed August 4, 2026; the same filing records that its license for NXP200 from Haisco became effective on July 1, 2026 when the public offering closed.
• The same release reports a public offering completed in July 2026 for gross proceeds of $115 million, which the company says extends its cash runway into the first half of 2029.

Practical opening

“Its CEO restated on September 24, 2026 that the US IND for NXP200 goes in this quarter. Its own US Phase 1 records list no CRO and name company staff as contacts. That suggests the vendor for the first US NXP200 study is being chosen now. We could offer its development chief a first-in-human site plan before the IND goes in.”

Claim boundaryDo not say Nuvectis has not chosen a CRO for NXP200, that it is out to bid, that the money is earmarked for oncology, or that NXP200 has had an FDA pre-IND meeting; that bullet belongs to ciprocopan.

Shay Shemesh is a career clinical-operations executive (Keryx, Stemline) who has run NXP800 and NXP900 Phase 1 work since 2021; a buyer like that reuses the vendors he knows, which is the real risk, not budget.

Decision ownerShay Shemesh, Executive Vice President, Chief Development and Operations Officer · LinkedIn: https://www.linkedin.com/in/shay-shemesh-395983335/ (from a search title, profile not opened) · Email not enriched for this preview

Evidence

• BigHat's Senior Director, Clinical Operations posting, dated July 17, 2026 on its own job board and still listed October 1, 2026, covers oncology and inflammatory disease and assigns oversight of vendor selection and management including CROs.
• BigHat's September 24, 2026 release announces completion of a $75 million Series C bringing total funding to $223 million, and states that the company plans to begin human trials of BHB299 in 2027.
• BigHat Biosciences' about page, read October 1, 2026, describes a San Mateo, California antibody company with overview tiles of 85+ employees and $223M in funding, and its leadership list carries no chief medical officer or clinical operations title.

Practical opening

“It closed a $75 million Series C on September 24, 2026 and plans BHB299 human trials in 2027. Its posting for the clinical-operations lead, still listed on October 1, 2026, assigns vendor selection including CROs. That suggests the next CRO decision sits with a hire who has not started yet. We could offer John Corbin a BHB299 first-in-human plan before the hire starts.”

Claim boundaryDo not say BigHat has no CRO, that it is re-bidding its vendors, or that the posting is new; it has been open since July and may be filled.

The first study runs at a Phase 1 site network with no CRO visible, so the sponsor may repeat that model for BHB299 and buy only functional services.

Decision ownerJohn Corbin, Chief Development Officer · LinkedIn: https://www.linkedin.com/in/john-corbin-10b2b7b/ (from a search title, profile not opened) · Email not enriched for this preview

Evidence

• NextPoint's Form D, filed with the SEC on July 30, 2026, reports $33,728,772 (about $33.7 million) sold of a $48,729,165 offering to 15 investors, with the date of first sale July 22, 2026.
• NextPoint's news page, read on October 1, 2026, carries the February 9, 2026 NPX372 clinical-entry release as its newest item and no announcement of the July 2026 financing.
• NextPoint's pipeline page, undated and read on October 1, 2026, states that NPX125, a B7-H7-targeted DAR8 antibody-drug conjugate with a novel linker, has an IND filing planned for late 2026.
• NextPoint's Phase 1 record for NPX267, last updated June 27, 2025, is suspended for a stated Business decision after a July 2023 start; a third Phase 1 (NCT06240728, NPX887) has not been updated since June 2025, so NPX125 would be its fourth first-in-human.

Practical opening

“It filed a Form D on July 30, 2026 reporting $33.7 million sold. Its pipeline page, as read on October 1, 2026, plans an IND for the NPX125 antibody-drug conjugate in late 2026. That suggests the window for this study is closing, so the real opening is the study after it. We could ask Leena Gandhi whether the ADC study's vendors are set yet.”

Claim boundaryDo not say the CRO decision for NPX125 is open, that NextPoint has no vendors, that the raise is a Series C, or who invested; the record shows none of that.

NPX125 is the company's fourth first-in-human since 2023, one earlier study is suspended for a business decision and another is stale, and an IND in late 2026 means its CRO was likely chosen already; a call this week is late for this study.

Decision ownerLeena Gandhi, Chief Medical Officer · LinkedIn: https://www.linkedin.com/in/leena-gandhi-96abb66/ (from a search title, profile not opened) · Email not enriched for this preview